MetaCap

Minerva Neurosciences (NERV) vs PDS Biotechnology (PDSB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PDS Biotechnology (PDSB) has outperformed Minerva Neurosciences (NERV) over the past year, gaining 3.0% versus a loss of 49.2%. Over five years, NERV leads with a -76.4% price change compared with -92.5% for PDSB. Minerva Neurosciences is the larger company by market cap ($99.7 million vs $95.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NERV-49.24%PDSB+2.97%
+121%+19%-83%
Nov 21, 20251 yearNov 20, 2026
NERV-77.68%PDSB-92.26%
+57%-24%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NERV versus PDSB key metrics
MetricNERVPDSB
Share price$2.00$0.7774
Market cap$99.67M$95.39M
1-day change-5.66%-3.70%
YTD return-50.25%+0.96%
1-year return-49.24%+2.97%
5-year return-76.42%-92.46%
EPS (TTM)$-33.83$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-293.42M$-34.50M
52-week high$8.80$1.79
52-week low$1.96$0.195
Distance from 52-week high-77.27%-56.57%
Analyst consensusbuystrong_buy
Avg. price target upside+416.50%+478.85%
Average volume164.71K25.64M
Shares outstanding49.84M122.70M
Employees721
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PDSB has outperformed NERV by 52.2 percentage points over the past year.

About Minerva Neurosciences

NERV stock →

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About PDS Biotechnology

PDSB stock →

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

NERV vs PDSB FAQ

Which is bigger, Minerva Neurosciences or PDS Biotechnology?

Minerva Neurosciences (NERV) is larger, with a market capitalization of $99.67M compared with $95.39M for PDS Biotechnology (PDSB).

Which stock has performed better over the past year, NERV or PDSB?

PDSB returned +2.97% over the past 12 months, compared with -49.24% for NERV (price return, excluding dividends). Past performance does not predict future results.

Are Minerva Neurosciences and PDS Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons